The European Medicine Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommends that Genmab's Darzalex be authorized for use in combination with cancer treatment Velcade and drugs cyclophosphamide and dexamethasone for treating adults with systemic light-chain (AL) amyloidose.
This recommendation encompasses the injection-based version of Darzalex which is marketed as Darzalex SC in the EU and as Darzalex Faspro on other markets, according to a Genmab press release on Friday afternoon.
Aside from the treatment of AL amyloidosis, the CHMP also recommends that Darzalex SC is used in combination with celgene's imnovid and dexamenthason for treating patients with multiple myeloma who have received at least one prior therapy containing a proteasome inhibitor (PI) and lenalidomide, or who have demonstrated disease progression in spite of having received at least two prior therapies that included lenalidomide and a proteasome inhibitor (PI).
Formally, the application for EU marketing authorization was submitted by Genmab's official partner Janssen.
Analysts to home in on expenses in Genmab's Wednesday fiscal report
Janssen had better Darzalex sales than expected in Q1
Genmab CEO on possible settlement in dispute with Janssen: "I have no comment"
More from MedWatch
CHMP to remove 100 generic medicines from market
Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.
Germany orders 40,000 monkeypox vaccines from Bavarian Nordic
The German Minister for Health has revealed that the German state has ordered vaccines from Bavarian Nordic, as the country reports 5 cases of monkeypox.
New head of research at Astellas Gene Therapies: "Choosing the right indications is extra important"
Morten Søgaard is leaving Pfizer to join Astellas, where he will be in charge of 100 employees. Going from one of the world largest pharmaceutical firms to a considerably smaller one will be a challenge, he says.
Rumored purchase of GN Group could mean divestment of hearing aid division, says media
Inside Business has learned that a number of buyers might be looking to buy GN Store Nord stock while it’s cheap, with the plan to sell one division, GN Hearing, while keeping Audio.
EMA publishes new plan to support antibiotic development
Drug-resistant bacteria kill hundreds of thousands of people every year, and national regulatory forces across the world are now coming together to ensure a uniform approach to clinical trials for antibiotics.
Quality System Manager 
System Sales Development Consultant - Investment Projects, Merck Millipore 
Key Account Manager, Europe and Asia 
Analytical Senior Scientist 
Client Talent Acquisition Specialist 
Production Director 
(Senior) Drug Substance Specialist 
Scientific Writer 
IRT Manager, Clinical Drug Supply 
Senior Chemical Safety Advisor 
Director Global Engineering 
CMO Operations Specialist - screening & selection of CMO/CDMO’s 
Innovation Project Manager, Display Unit 
Nordic Medical Affairs Manager 
KLIFO is looking for a Clinical Supply Manager for our Glostrup office 
Account Manager 
Director for innovative pre-clinical testing unit